• Something wrong with this record ?

Rituximab induces rapid blood repopulation by CLL cells mediated through their release from immune niches and complement exhaustion

M. Borsky, V. Hrabcakova, J. Novotna, Y. Brychtova, M. Doubek, A. Panovska, P. Muller, J. Mayer, M. Trbusek, M. Mraz

. 2021 ; 111 (-) : 106684. [pub] 20210804

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

The in vivo rituximab effects in B cell malignancies are only partially understood. Here we analyzed in a large chronic lymphocytic leukemia (CLL) cohort (n = 80) the inter-patient variability in CLL cell count reduction within the first 24 h of rituximab administration in vivo, and a phenomenon of blood repopulation by malignant cells after anti-CD20 antibody therapy. Larger CLL cell elimination after rituximab infusion was associated with lower pre-therapy CLL cell counts, higher CD20 levels, and the non-exhausted capacity of complement-dependent cytotoxicity (CDC). The absolute amount of cell-surface CD20 molecules (CD20 density x CLL lymphocytosis) was a predictor for complement exhaustion during therapy. We also describe that a highly variable decrease in CLL cell counts at 5 h (88 %-2%) following rituximab infusion is accompanied in most patients by peripheral blood repopulation with CLL cells at 24 h, and in ∼20 % of patients, this resulted in CLL counts higher than before therapy. We provide evidence that CLL cells recrudescence is linked with i) CDC exhaustion, which leads to the formation of an insufficient amount of membrane attack complexes, likely resulting in temporary retention of surviving rituximab-opsonized cells by the mononuclear-phagocyte system (followed by their release back to blood), and ii) CLL cells regression from immune niches (CXCR4dimCD5bright intraclonal subpopulation). Patients with major peripheral blood CLL cell repopulation exhibited a longer time-to-progression after chemoimmunotherapy compared to patients with lower or no repopulation, suggesting chemotherapy vulnerability of CLL cells that repopulate the blood.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011839
003      
CZ-PrNML
005      
20220506130106.0
007      
ta
008      
220425s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.leukres.2021.106684 $2 doi
035    __
$a (PubMed)34438120
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Borsky, Marek $u Dept. of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 625 00, Brno, Czech Republic
245    10
$a Rituximab induces rapid blood repopulation by CLL cells mediated through their release from immune niches and complement exhaustion / $c M. Borsky, V. Hrabcakova, J. Novotna, Y. Brychtova, M. Doubek, A. Panovska, P. Muller, J. Mayer, M. Trbusek, M. Mraz
520    9_
$a The in vivo rituximab effects in B cell malignancies are only partially understood. Here we analyzed in a large chronic lymphocytic leukemia (CLL) cohort (n = 80) the inter-patient variability in CLL cell count reduction within the first 24 h of rituximab administration in vivo, and a phenomenon of blood repopulation by malignant cells after anti-CD20 antibody therapy. Larger CLL cell elimination after rituximab infusion was associated with lower pre-therapy CLL cell counts, higher CD20 levels, and the non-exhausted capacity of complement-dependent cytotoxicity (CDC). The absolute amount of cell-surface CD20 molecules (CD20 density x CLL lymphocytosis) was a predictor for complement exhaustion during therapy. We also describe that a highly variable decrease in CLL cell counts at 5 h (88 %-2%) following rituximab infusion is accompanied in most patients by peripheral blood repopulation with CLL cells at 24 h, and in ∼20 % of patients, this resulted in CLL counts higher than before therapy. We provide evidence that CLL cells recrudescence is linked with i) CDC exhaustion, which leads to the formation of an insufficient amount of membrane attack complexes, likely resulting in temporary retention of surviving rituximab-opsonized cells by the mononuclear-phagocyte system (followed by their release back to blood), and ii) CLL cells regression from immune niches (CXCR4dimCD5bright intraclonal subpopulation). Patients with major peripheral blood CLL cell repopulation exhibited a longer time-to-progression after chemoimmunotherapy compared to patients with lower or no repopulation, suggesting chemotherapy vulnerability of CLL cells that repopulate the blood.
650    _2
$a protinádorové látky imunologicky aktivní $x terapeutické užití $7 D000074322
650    _2
$a komplement $x imunologie $7 D003165
650    _2
$a cytotoxicita imunologická $x imunologie $7 D003602
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a chronická lymfatická leukemie $x krev $x farmakoterapie $x imunologie $x patologie $7 D015451
650    _2
$a rituximab $x terapeutické užití $7 D000069283
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hrabcakova, Viera $u Dept. of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 625 00, Brno, Czech Republic
700    1_
$a Novotna, Jitka $u Dept. of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 625 00, Brno, Czech Republic
700    1_
$a Brychtova, Yvona $u Dept. of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 625 00, Brno, Czech Republic
700    1_
$a Doubek, Michael $u Dept. of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 625 00, Brno, Czech Republic
700    1_
$a Panovska, Anna $u Dept. of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 625 00, Brno, Czech Republic
700    1_
$a Muller, Petr $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic
700    1_
$a Mayer, Jiri $u Dept. of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 625 00, Brno, Czech Republic
700    1_
$a Trbusek, Martin $u Dept. of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 625 00, Brno, Czech Republic. Electronic address: m.trbusek@volny.cz
700    1_
$a Mraz, Marek $u Dept. of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 625 00, Brno, Czech Republic; Center of Molecular Medicine, Central European Institute of Technology (CEITEC), Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic. Electronic address: marek.mraz@email.cz
773    0_
$w MED00003141 $t Leukemia research $x 1873-5835 $g Roč. 111, č. - (2021), s. 106684
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34438120 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130058 $b ABA008
999    __
$a ok $b bmc $g 1789445 $s 1163040
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 111 $c - $d 106684 $e 20210804 $i 1873-5835 $m Leukemia research $n Leuk Res $x MED00003141
LZP    __
$a Pubmed-20220425

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...